Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study GlobeNewswire November 04, 2025 Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase […]

Standard BioTools Reports Third Quarter 2025 Financial Results GlobeNewswire November 04, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025. Recent Highlights: Third quarter 2025 total combined company revenue of $46.2 million;

(NasdaqGM:RAPT), SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in November:

(NYSE:RAMP), SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) — LiveRamp(R) (NYSE: RAMP), a leading data collaboration platform, today announced that its CFO Lauren Dillard will present at the Wells Fargo 9th Annual TMT Summit in Rancho Palos Verdes, CA on Tuesday, November 18th at 12:45 p.m. PT / 3:45 p.m. ET. Links to the live

(NASDAQ:SANA), SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the TD Cowen Immunology & Inflammation Summit at 1:30 p.m. ET on Wednesday, November 12, 2025. The presentation will feature a

(NYSE:PFLT),(TASE:PFLT.TA), MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) declares its monthly distribution for November 2025 of $0.1025 per share, payable on December 1, 2025 to stockholders of record as of November 17, 2025. The distribution is expected to be paid from taxable net investment income. The

(NASDAQ:SYRE), Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A inhibition in rheumatoid arthritis (“RA”), psoriatic arthritis (“PsA”), and axial spondyloarthritis (“axSpA”) On track for

(NasdaqGM:AIP), CAMPBELL, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP for accelerating semiconductor creation in the AI era, today announced that Altera has licensed Arteris' broad product portfolio for the development of next-generation FPGA and SoC FPGA solutions. Arteris IP and software products will be used

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire November 04, 2025 FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two

Ceribell Reports Third Quarter 2025 Financial Results GlobeNewswire November 04, 2025 SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025